Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
March 9, 2011

Kite Pharma Raises $15M in Initial Private Placement to Progress Anticancer Pipeline

  • Cancer immunotherapeutics firm Kite Pharma raised $15 million in an initial round of private financing with a syndicate of venture and qualified investors. The funds will be used to progress Los Angeles-based Kite’s lead products into clinical development and expand its preclinical pipeline.

    The young firm’s early clinical-stage anticancer candidate is an engineered virus-based alpha fetoprotein (AFP) vaccine designed to stimulate an immune response against AFP-expressing hepatocellular cancer. A Phase I/II clinical trial is currently under way. The Phase I component of the trial will monitor the toxicity of escalating doses of the engineered virus in order to identify a tolerable dose for the Phase II component and future studies. The Phase II stage will evaluate the treatment’s ability to elicit an immune response in a larger number of patients. The National Cancer Institute assisted in funding the AFP-vaccine platform, through its Rapid Access to Interventional Development program.

    Kite’s second lead program is based on its GM-CAIX technology. GM-CAIX is a chimeric molecule created by the fusion of the tumor-expressed antigen CAIX (G250; MN), with the immunostimulant GM-CSF. The fusion protein is then integrated into novel immunotherapy designed to to induce robust immune responses against a wide range of tumors expressing CAIX.

    The lead GM-CAIX program is an autologous dendritic cellular therapy that is initially being developed for the treatment of renal cancers, although other tumor indications will follow, Kite notes. IND-enabling preclinical testing is in progress.  

Related content

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: [email protected] An error has occurred. Please contact Customer Service at [email protected]
  • You’re all set! Thank you for subscribing to GEN Highlights.